Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/19/2025

Denosumab Therapy for Patients with History of Osteonecrosis of the Jaw (ONJ)

Introduction to Denosumab

  • The American College of Oncology recommends denosumab (60 mg subcutaneously every 6 months) as the next treatment for patients with a history of ONJ on ibandronate after completing two years of teriparatide (Forteo) therapy, due to its different mechanism of action than bisphosphonates and its ability to reduce fractures by 50% compared to placebo 1, 2

Rationale for Denosumab Selection

  • Denosumab is considered the most effective treatment option for patients with a history of ONJ who have completed teriparatide therapy, as it has a different mechanism of action than bisphosphonates 1, 2
  • Denosumab has a shorter half-life than bisphosphonates, which may be advantageous in patients with prior ONJ, as temporary discontinuation could potentially enhance ONJ resolution if needed 3

Important Considerations for Denosumab Therapy

  • Baseline dental examination is mandatory before initiating denosumab to assess ONJ risk, and serum calcium levels must be measured and any hypocalcemia corrected before starting treatment, according to the American College of Oncology 4
  • Regular monitoring of serum calcium is necessary, especially after the first few doses, and calcium supplementation (500-1000 mg/day) and vitamin D supplementation are required during treatment, as recommended by the American College of Oncology 4

Contraindications and Cautions

  • Avoid invasive dental procedures when possible during denosumab therapy, and if dental procedures are necessary, consider the timing carefully in relation to denosumab administration, as advised by the American College of Oncology 5
  • Hypocalcemia is a contraindication and must be corrected before starting denosumab, according to the American College of Oncology 4

Alternative Options

  • Romosozumab could be considered as an alternative option, but there are concerns about increased risk of myocardial infarction, stroke, and death, as reported by the American College of Rheumatology 6

Monitoring Recommendations

  • Measure bone mineral density (BMD) every 1-2 years during treatment, and monitor serum calcium before each denosumab injection, as recommended by the American College of Rheumatology 6, 4

Duration of Therapy

  • Denosumab is typically administered for up to 5 years, and abrupt discontinuation should be avoided as it can lead to rebound bone loss and increased fracture risk, according to the American College of Oncology 1, 2, 4